March 19, 2021 7:35am
After 2 positive (Monday, Wednesday) and 2 negative (Tuesday, Thursday) closes; the IBB being up three (3) sessions and the XBI up two (2) sessions with the CBOE Volatility Index (VVIX) spending three (3) sessions down
Pre-open indications: 4 BUYs and 2 SELLs; Mentioned: BSTG, SDBB, AGTC, PSTI, CRSP, EDIT
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Dow futures are UP +0.15% (+50 points), S&P futures are UP +0.29% (+11 points) and NASDAQ futures are UP +0.55% (+70 points)
U.S. stock futures were modestly higher early Friday
U.S. stock futures were modestly higher after a spike in bond yields reignited concerns about stock valuations and prompted a sell-off in U.S. markets
Asia-Pacific markets fell as investor sentiment turned cautious, following an overnight selloff stateside
Markets struggled on Thursday, with the cell and gene therapy sector being sold-off as the Nasdaq fell 3%.
The weakness in stocks Thursday was caused by a spike in bond yields, with the benchmark 10-year Treasury yield breaking above 1.7%, its highest level since January of last year.
Remember we are getting closer to the end of the month and quarter
Thursday’s evening’s recap: “falling knives draw equity blood. Remember, a falling knife can quickly rebound - in what's known as a whipsaw If timed” … https://www.regmedinvestors.com/articles/11822
- The Nasdaq closed DOWN -409.03 points (-3.02%);
- the IBB closed down -3.10% and XBI closed down -4.77%
- Sector volume was LOW with 2 of the 4-upside having higher than the 3-month average volume with the volume of 3 of 29-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +2.35. points or +12.22% at 21.58;
- Thursday’s percentage (%) of the 4-upside were +0.46% (RENE.L) to +13.45% (VCEL) while the 29-downside ranges from -0.38% (AXGN) to -9.20% (SLDB);
March: 6 positive, 7 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining Sell: Questions continue …
Biostage (BSTG) closed up +$0.02 to $1.32 with 375 shares traded after Wednesday’s flat at $1.30 with 36 shares traded, Tuesday’s +$0.02 to $1.30 with 210 shares traded, Monday’s +$0.02 to $1.28 with 425 shares traded and Friday’s -$0.11 to $1.26 with 4,069 shares traded i.e., “pumped”.
Question#1: Notice WHEN the stock price is NOT being “pumped and minimally promoted” it barely trades?
Question#2: WHEN are the 10-K and 10-Q filings due?
Question#3: RSM US LLP, WHAT will your opinion of these operational issues and focus be?
MINORITY PUBLIC shareholders are waiting, watching and weighting responses to MAINTAIN their RIGHTS.
Solid Biosciences (SLDB) closed down -$0.60 to $6.05 after Wednesday’s +$0.22 to $6.65, Tuesday’s $6.43 and Monday’s $9.51 with a negative -$0.40 or -6.02% aftermarket indication after announcing an $85 million public offering.
Applied Genetic Technologies (AGTC) closed down -$0.05 to $5.75 after Wednesday’s +$0.04 to $5.80, Tuesday’s $5.76 and Monday’s $5.87 with a positive +$0.15 or +2.6`% pre-market indication.
Pluristem (PSTI) closed up $0.19 to $5.46 after Wednesday’s $5.27, Tuesday’s $5.30, Monday’s $5.51 and last Friday’s $5.43 with a positive +0.21 or +3.85% pre-market indication
From SELL to BUY:
CRISPR Therapeutics (CRSP) closed down -$7.53 to $123.57 after Wednesday’s +$0.53 to $131.10, Tuesday’s +$3.03 to $130.57, Monday’s +$2.99 to $133.60 and last Friday’s -$3.27 to $130.61 with a positive +$2.69 or +2.18% pre-market indication.
Editas Medicine (EDIT) closed down -$3.32 to $43.25 after Wednesday’s +$0.90 to $46.57, Tuesday’s -$2.30 to $45.67, Monday’s +$1.69 to $47.97 and last Friday’s -$1.04 to $46.28 with a positive +$0.25 or +0.58% aftermarket indication.
The BOTTOM LINE: I see a mix of BUYs and SELLs but, can’t count on being right as this market and sub-set sector is very capricious with short-term spurts through the mist of momentum and algorithmic rules.
A good quote from others, ““If you look at the price pattern on a day-to-day basis for the last now seven days, we’ve got a ping-pong match going on. One day it’s been growth, one day it’s been value,” said Mullaney. “I’m not sure if that’s indicating we’re at some kind of inflection point where growth might get a bounce here.”
I STILL am a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim … if one can!”
Many talk of horizons; “as I have said last week, my horizon is usually a Friday’s close …”
Thanks, the week is over, o-dark-100 comes too early …
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.